Transcriptomic and metabolic profiling of Tolvaptan treated Autosomal dominant polycystic kidney disease (ADPKD) patient.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology（2022）
摘要
Our data indicates a potential molecular mechanism of Tolvaptan treatment in regulating the integrity of tight junction and kidney cells, and provides novel therapeutic targets in in ADPKD.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要